Investigational study on immunomodulatory effect of lenvatinib in clinical specimens - Future oriented approach for lenvatinib on tumor microenvironment and cancer regression (FLORENCE) -

Investigational study on immunomodulatory effect of lenvatinib in clinical specimens - Future oriented approach for lenvatinib on tumor microenvironment and cancer regression (FLORENCE) - - FLORENCE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044924

Enrollment

Registered

2021-07-20

Start date

2021-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients in this study have advanced hepatocellular carcinoma and administered lenvatinib as first line treatment in Hiroshima university hospital. All patients in this study provide written informed consent. The details of inclusion and exclusion criteria are written in the following section.

Exclusion criteria

Exclusion criteria: Lenvatinib was administered after second-line therapy Informed consent for analysis was withdrawn

Design outcomes

Primary

Measure	Time frame
To evaluate the immuno-stimulatory effect of lenvatinib and the change of immune system through lenvatinib treatment using tumor samples by identifying immune cell profiling in tumor tissue before and after lenvatinib treatment	—

Secondary

Measure	Time frame
Progression-free survival, Overall survival	—

Countries

Japan

Contacts

Public ContactMasami Yamauchi

Hiroshima University Hospital Department of Clinical Oncology

myamauchi@hiroshima-u.ac.jp0822575193

Outcome results